BioAge Labs Company Insiders
| BIOA Stock | 20.69 2.84 15.91% |
BioAge Labs' insiders are aggressively buying. The analysis of insiders' sentiment of trading BioAge Labs stock suggests that vertually all insiders are extremely bullish at this time. BioAge Labs employs about 62 people. The company is managed by 14 executives with a total tenure of roughly 145 years, averaging almost 10.0 years of service per executive, having 4.43 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-10-03 | Vijay Satyanand Pande | Acquired 25306 @ 19.9 | View | ||
| 2024-10-01 | Vijay Satyanand Pande | Acquired 126793 @ 19.73 | View | ||
| 2024-09-27 | Vijay Satyanand Pande | Acquired 900000 @ 18 | View |
Monitoring BioAge Labs' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. BioAge Labs Management Team Effectiveness
The company has return on total asset (ROA) of (0.1746) % which means that it has lost $0.1746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2564) %, meaning that it created substantial loss on money invested by shareholders. BioAge Labs' management efficiency ratios could be used to measure how well BioAge Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of January 13, 2026, Return On Tangible Assets is expected to decline to -0.19. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, BioAge Labs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Non Current Assets Total are forecasted to decline to about 967 K.The current year's Common Stock Shares Outstanding is expected to grow to about 18.6 MBioAge Labs holds a total of 35.86 Million outstanding shares. Over half of BioAge Labs' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 35.9 M | Current Value 35.9 M | Avarage Shares Outstanding 26.1 M | Quarterly Volatility 11.3 M |
BioAge Labs Workforce Comparison
BioAge Labs is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 25,695. BioAge Labs adds roughly 62.0 in number of employees claiming only tiny portion of equities under Health Care industry.
BioAge Labs Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAge Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAge Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BioAge Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-12-01 | 0.5 | 2 | 4 | 86,897 | 173,794 |
| 2017-06-01 | 7.0 | 7 | 1 | 405,000 | 0.00 |
| 2016-03-01 | 5.0 | 5 | 1 | 406,000 | 200,000 |
| 2015-12-01 | 0.5 | 1 | 2 | 154,700 | 181,978 |
| 2015-09-01 | 2.0 | 4 | 2 | 46,200 | 20,000 |
| 2014-12-01 | 2.3333 | 7 | 3 | 365,000 | 108,083 |
BioAge Labs Notable Stakeholders
A BioAge Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioAge Labs often face trade-offs trying to please all of them. BioAge Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioAge Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kristen Fortney | CEO, CoFounder | Profile | |
| Eric MD | COO CoFounder | Profile | |
| Rusty Montgomery | Senior Research | Profile | |
| Julie Gammelgard | Senior People | Profile | |
| MD MBA | Chief Officer | Profile | |
| Justin Rebo | Senior Biology | Profile | |
| Patrick MD | Senior Science | Profile | |
| Paul MD | Chief Research | Profile | |
| Peng MBA | Chief Aging | Profile | |
| Ann BSN | Chief Officer | Profile | |
| MBA MBA | Chief Aging | Profile | |
| BJ Sullivan | Chief Officer | Profile | |
| Ralph Scarborough | Vice Accounting | Profile | |
| CarrieLynn Furr | Senior Affairs | Profile |
About BioAge Labs Management Performance
The success or failure of an entity such as BioAge Labs often depends on how effective the management is. BioAge Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioAge management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioAge management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.25) | (0.24) |
Please note, the presentation of BioAge Labs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioAge Labs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioAge Labs' management manipulating its earnings.
BioAge Labs Workforce Analysis
Traditionally, organizations such as BioAge Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioAge Labs within its industry.BioAge Labs Manpower Efficiency
Return on BioAge Labs Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 5.1M | |
| Working Capital Per Employee | 5.3M | |
| Working Capital Per Executive | 23.5M |
Complementary Tools for BioAge Stock analysis
When running BioAge Labs' price analysis, check to measure BioAge Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAge Labs is operating at the current time. Most of BioAge Labs' value examination focuses on studying past and present price action to predict the probability of BioAge Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAge Labs' price. Additionally, you may evaluate how the addition of BioAge Labs to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |